Calls for papers
-
Alexza Pharmaceuticals has promoted Catherine McAuliffe to VP, Operations and Stacy Palermini to VP, Finance, the company said. McAuliffe most recently served as Executive Director, Operations; the position of VP, Operations is newly created. Palermini… Read more . . .
-
GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies’ PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in… Read more . . .
-
Verona Pharma has announce that data from the third part of single ascending dose (SAD)/multiple ascending dose (MAD) trial of nebulized RPL554 in COPD patients show that the formulation was well tolerated at all doses… Read more . . .
-
Hovione, which offers a wide range of inhalation drug development and manufacturing services, has announced that it will add 30,600 sq ft and a new commercial spray dryer to its East Windsor, NJ facility. The… Read more . . .
-
Boehringer Ingelheim has announced new data from the ENERGITO and OTEMTO studies of the Stiolto tiotropium/olodaterol Respimat inhaler for the treatment of COPD. The FDA approved Stiolto Respimat in May 2015; in Europe, where the… Read more . . .
-
Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app.… Read more . . .
-
OptiNose has announced positive results from the NAVIGATE I Phase 3 trial of its OPN-375 intranasal fluticasone for the treatment of nasal polyposis demonstrating statistically significant reduction of symptoms and total polyp grade. In June… Read more . . .
-
Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor “to assist in exploring strategic options to enhance stockholder value,” the company said. Options being explored include selling corporate assets, a strategic business combination, or… Read more . . .
-
Insys Therapeutics has announced that it will partner with Senzer Ltd, a subsidiary of Kind Consumer, to develop inhaled dronabinol (THC) and cannabidiol (CBD) products. Insys has licensed Senzer’s delivery technology, the same technology in… Read more . . .
-
Adapt Pharma announced that the FDA has accepted its filing and granted priority review to its New Drug Application for Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose. Adapt submitted the NDA… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA